KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
KRAS mutations are the most frequent molecular abnormalities found in one out of four nonsmall cell lung cancers (NSCLC). Their incidence increases in cases of adenocarcinoma, smokers and Caucasian patients. Their negative value in terms of prognosis and responsiveness to both standard chemotherapy...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2016-03-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/25/139/71.full |